Deleted ICD-10-PCS Code XW03392 Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2

New Technology›Anatomical Regions›Introduction
  • Deleted — Not Valid for Claims
  • Valid FY 2020–2022
  • Deleted in FY 2023
CMS Source: CMS ICD-10-PCS code files FY 2020–2022 and the ICD-10-PCS conversion table.
Do not report XW03392 for inpatient discharges on or after October 1, 2022. Claims with a deleted code are rejected. Use one of the replacement codes below.

XW03392 is a deleted ICD-10-PCS code, removed from the code set effective October 1, 2022. It was valid for introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2 on inpatient discharges from October 1, 2019 through September 30, 2022, and later discharges must use a current code. The CMS conversion table maps it to 3E033GC.

Replacement Codes for XW03392

The CMS ICD-10-PCS conversion table maps XW03392 to this code. Confirm the choice against the procedure documentation and the code page's table.

  • 3E033GC Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach

Current Codes Starting With XW03

Active FY 2027 codes that share the first 4 characters of XW03392 (same table and body part).

  • XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0330B Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0331B Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0336C Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
  • XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0337C Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12
  • XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0339A Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033CA Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033DA Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033FB Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033K9 Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
  • XW033L6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

See the full XW0 table →

Code History

FY 2020AddedAdded to the ICD-10-PCS code setEffective October 1, 2019.
FY 2022Last fiscal year the code was validValid for discharges through September 30, 2022.
FY 2023DeletedRemoved from the ICD-10-PCS code setEffective October 1, 2022.

Questions About XW03392

Is XW03392 still a valid ICD-10-PCS code?

No. XW03392 was deleted from ICD-10-PCS effective October 1, 2022, with the FY 2023 code set. It cannot be reported for inpatient discharges on or after that date.

What replaced XW03392?

The CMS ICD-10-PCS conversion table maps XW03392 to 3E033GC. Confirm it matches the procedure documentation before you use it; a conversion is a starting point, not an automatic substitution.

Can I still use XW03392 for older discharges?

Yes, for inpatient discharges from October 1, 2019 through September 30, 2022. ICD-10-PCS codes are assigned by the code set in effect on the date of discharge, so a corrected or late claim for a discharge in that window still uses XW03392.